Sequentia Biotech is a deeptech bioinformatics company focused on the analysis and application of omics data across clinical, industrial, and research settings. Its flagship platform, MICK, provides state-of-the-art data analysis and interpretation to enable deeper exploration of microbiome data and translate findings into actionable insights. The company positions MICK for use in clinical decision-making as well as applications in biomedicine, agritech (crop protection and nutrition) and the food industry (improving production and quality). Sequentia says the €10 million Series A equity investment will accelerate the market introduction and expansion of MICK and scale up its bioinformatics enabling technologies. The funding is intended to support an ambitious go-to-market strategy and broader adoption by researchers and healthcare professionals. The company is headquartered in Barcelona, Spain.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2024